Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction

被引:5
|
作者
Ahn, Sun Tae [1 ]
Lee, Dong Hyun [1 ]
Jeong, Hyeong Guk [1 ]
Kim, Jong Wook [1 ]
Oh, Mi Mi [1 ]
Park, Hong Seok [1 ]
Moon, Du Geon [1 ]
机构
[1] Korea Univ, Dept Urol, Guro Hosp, 148 Gurodong Ro, Seoul 08308, South Korea
关键词
Fixed-dose; Medication persistence; Tadalafil; Tamsulosin; URINARY-TRACT SYMPTOMS; OVERACTIVE BLADDER; MEN; THERAPY; SAFETY; EFFICACY;
D O I
10.4111/icu.2020.61.1.81
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The primary aim of this study was to assess treatment persistence with a fixed-dose combination (FDC) of tadalafil (5 mg) and tamsulosin (0.4 mg). This study also evaluated the reasons for early treatment discontinuation. Materials and Methods: This retrospective observational study included patients with benign prostatic hyperplasia and erectile dysfunction who started an FDC treatment of tadalafil (5 mg) and tamsulosin (0.4 mg) between July 2017 and February 2018. Treatment persistence and reasons for early discontinuation were evaluated during the first 6 months. The cumulative discontinuation rate and differences in various parameters were assessed using Kaplan-Meier analysis and the log-rank test, respectively. Factors related to persistence were analyzed using a Cox proportional hazard model. Results: Overall, 97 patients were included in the study. The cumulative persistence rate at 30, 90, and 180 days was 88.7%, 66.0%, and 54.6%, respectively. The cumulative persistence over 6 months differed significantly according to the administration of FDC therapy (log-rank p=0.005) and age (log-rank p=0.024). Younger patients (odds ratio, 2.049; p=0.021) and treatment-naive patients (odds ratio, 2.461; p=0.006) were more likely to discontinue therapy within 6 months. The common reasons for discontinuing therapy were side effects (63.6%) and perceived poor efficacy (22.7%). Conclusions: Side effects were reported to be the main reason for treatment discontinuation. Thus, to improve compliance for a once-daily FDC of tadalafil (5 mg) and tamsulosin (0.4 mg), it is recommended to select patients who show adaptation to a combination of a-blockers and phosphodiesterase type 5 inhibitors prior to FDC treatment.
引用
收藏
页码:81 / 87
页数:7
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS OF ADDING A NEW FIXED-DOSE COMBINATION THERAPY OF DUTASTERIDE AND TAMSULOSIN TO THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA IN QUEBEC, CANADA
    Ismaila, A.
    Posnett, J.
    Walker, A.
    Sayani, A.
    Robson, R. C.
    Su, Z.
    VALUE IN HEALTH, 2012, 15 (04) : A193 - A193
  • [22] Administration of daily 5mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia
    Amano, Toshiyasu
    Earle, Carolyn
    Imao, Tetsuya
    Matsumoto, Yuki
    Kishikage, Takahiro
    AGING MALE, 2018, 21 (01): : 77 - 82
  • [23] Effect of tadalafil 5 mg daily treatment on penile haemodynamics in patients with erectile dysfunction
    Gasanz, Carlos
    Moreno-Mendoza, Daniel
    Fernando Villegas, Juan
    Fernanda Peraza, Maria
    Sarquella, Joaquim
    Ruiz-Castane, Eduard
    Sanchez-Curbelo, Josvany
    REVISTA INTERNACIONAL DE ANDROLOGIA, 2022, 20 (01): : 49 - 53
  • [24] Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
    Eisen, Christoph
    Lulic, Zrinka
    Manuel Palacios-Moreno, Juan
    Adalig, Burkay
    Hennig, Michael
    Cortes, Vanessa
    Gilg, Florian
    Kostev, Karel
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (01) : 37 - 49
  • [25] COMBINATION OF TAMSULIN (0.4 MG) AND DUTASTERIDE (5 MG) FOR BENIGN PROSTATIC HYPERPLASIA. OBJECTIVE ANALYSIS OF STROMAL COMPONENTS OF THE TRANSITION ZONE
    Cavalcanti, Andre
    Restrepo, Felipe
    Costa, Waldemar
    Gallo, Carla
    Pereira, Bruna
    Machado, Nathalia
    Sampaio, Francisco
    JOURNAL OF UROLOGY, 2014, 191 (04): : E669 - E669
  • [26] The Authors Reply: Reply on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients"
    Kim, Su Jin
    Shin, In-Soo
    Eun, Sung-Jong
    Whangbo, Taeg-Keun
    Kim, Jin Wook
    Cho, Young Sam
    Kim, Joon Chul
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2017, 21 (03) : 231 - 232
  • [27] Letter to the Editor: Commentary on "Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients"
    Tae, Bum Sik
    Choi, Hoon
    Bae, Jae Hyun
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2017, 21 (03) : 229 - 230
  • [28] The efficacy of mirabegron 50 mg additional therapy on tamsulosin 0.2 mg/0.4 mg and dutasteride 0.5 mg combination therapy for lower urinary tract symptoms of elderly treatment-naive benign prostatic hyperplasia patients: prospective analysis
    Chung, H. S.
    Lee, H. -Y.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 20 - 20
  • [29] Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
    AbdelRazek, Mostafa
    Abolyosr, Ahmad
    Mhammed, Omar
    Fathi, Atef
    Talaat, Mohammed
    Hassan, Ahmed
    WORLD JOURNAL OF UROLOGY, 2022, 40 (08) : 2063 - 2070
  • [30] A Randomized, Placebo-Controlled Study to Assess Safety and Efficacy of Vardenafil 10 mg and Tamsulosin 0.4 mg vs. Tamsulosin 0.4 mg Alone in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
    Gacci, Mauro
    Vittori, Gianni
    Tosi, Nicola
    Siena, Giampaolo
    Rossetti, Mario Alberto
    Lapini, Alberto
    Vignozzi, Linda
    Serni, Sergio
    Maggi, Mario
    Carini, Marco
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 (06): : 1624 - 1633